跳至主要内容
临床试验/NCT04706845
NCT04706845已完成不适用

Understanding the Burden of ACC Through the Eyes of Patients

Ayala Pharmaceuticals, Inc,1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2021年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
46
试验地点
1
主要终点
Key burdens related to the disease or treatments

研究概览

简要总结

This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor.

Primary Objectives:

  • To identify the specific burdens faced by patients with ACC
  • To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)

详细描述

This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor.

Primary Objectives:

  • To identify the specific burdens faced by patients with ACC
  • To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)

Secondary Objectives:

  • To assess QoL implication in patients living with ACC (Adenoid Cystic Carcinoma)
  • To compare the burdens and QoL impacts in people living with ACC, with their tumors bearing Notch mutations or Notch Wild Type due to:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Participant must be a person diagnosed with ACC who is 18 years or older
  • •For patients with metastatic disease; watchful waiting or progressive disease, participants must know the results of molecular profiling of their tumor
  • •Histologically-confirmed diagnosis of ACC with written proof of disease and molecular profile of tumor provided. This can be a note showing genetic diagnosis from a relevant testing laboratory, physician consult notes, a medical record of diagnosis, or any other single piece of documentation that connects your name/the patient's name with ACC.
  • •Able to read, write and understand English, Hebrew, Arabic, or Russian
  • •Able to grant informed consent
  • •Willing to participate in a 45-to-60-minute telephone interview, including follow up questions (if necessary)

排除标准

  • •Inability to meet any of the inclusion criteria

结局指标

主要结局

Key burdens related to the disease or treatments

时间窗: Q4-2021

Life impacts of those burdens for patient/family

时间窗: Q4-2021

次要结局

未报告次要终点

研究者

发起方
Ayala Pharmaceuticals, Inc,
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验